This publication is summarised in a BMJ review article. The new regimens evaluated in the review were: carfilzomib with lenalidomide and dexamethasone; elotuzumab with lenalidomide and dexamethasone; ixazomib with lenalidomide and dexamethasone; panobinostat with bortezomib and dexamethasone; pomalidomide with low dose dexamethasone; and daratumumab monotherapy.
The authors commented that discounts approaching 100% would be needed for certain drugs to achieve a value more closely aligned to their benefits because they are given in addition to treatments that already border cost effectiveness thresholds.
NICE TA338 does not recommend pomalidomide for the treatment of multiple myeloma.
NICE TA380 recommends the panobinostat as an option for relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent.